Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GW642444 dose-ranging crossover study in persistent asthma
2005-004419-31Phase 2Completed
- Sponsor
- GSK
- Start
- Feb 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vilanterol in asthma (5 arms), sponsored by GSK. Primary endpoint: Mean change from baseline in clinic visit trough FEV1 after 14 days of repeat dosing. Started Feb 2006; status: completed.
02
Drugs
vilanterol
03
Conditions
asthma
Beyond the preview
Go deeper on 2005-004419-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004419-31.